Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia Journal Article

Authors: Grever, M. R.; Abdel-Wahab, O.; Andritsos, L. A.; Banerji, V.; Barrientos, J.; Blachly, J. S.; Call, T. G.; Catovsky, D.; Dearden, C.; Demeter, J.; Else, M.; Forconi, F.; Gozzetti, A.; Ho, A. D.; Johnston, J. B.; Jones, J.; Juliusson, G.; Kraut, E.; Kreitman, R. J.; Larratt, L.; Lauria, F.; Lozanski, G.; Montserrat, E.; Parikh, S. A.; Park, J. H.; Polliack, A.; Quest, G. R.; Rai, K. R.; Ravandi, F.; Robak, T.; Saven, A.; Seymour, J. F.; Tadmor, T.; Tallman, M. S.; Tam, C.; Tiacci, E.; Troussard, X.; Zent, C. S.; Zenz, T.; Zinzani, P. L.; Falini, B.
Article Title: Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia
Abstract: Hairy cell leukemia is an uncommon hematologic malignancy characterized by pancytopenia and marked susceptibility to infection. Tremendous progress in the management of patients with this disease has resulted in high response rates and improved survival, yet relapse and an appropriate approach to retreatment present continuing areas for research. The disease and its effective treatment are associated with immunosuppression. Because more patients are being treated with alternative programs, comparison of results will require general agreement on definitions of response, relapse, and methods of determining minimal residual disease. The development of internationally accepted, reproducible criteria is of paramount importance in evaluating and comparing clinical trials to provide optimal care. Despite the success achieved in managing these patients, continued participation in available clinical trials in the firstline and particularly in the relapse setting is highly recommended. The Hairy Cell Leukemia Foundation convened an international conference to provide common definitions and structure to guide current management. There is substantial opportunity for continued research in this disease. In addition to the importance of optimizing the prevention and management of the serious risk of infection, organized evaluations of minimal residual disease and treatment at relapse offer ample opportunities for clinical research. Finally, a scholarly evaluation of quality of life in the increasing number of survivors of this now manageable chronic illness merits further study. The development of consensus guidelines for this disease offers a framework for continued enhancement of the outcome for patients. © 2011 by The American Society of Hematology; all rights reserved.
Journal Title: Blood
Volume: 129
Issue: 5
ISSN: 0006-4971
Publisher: American Society of Hematology  
Date Published: 2017-02-02
Start Page: 553
End Page: 560
Language: English
DOI: 10.1182/blood-2016-01-689422
PROVIDER: scopus
PMCID: PMC5290982
PUBMED: 27903528
Notes: Review -- Export Date: 3 April 2017 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Martin Stuart Tallman
    443 Tallman
  2. Jae Hong Park
    147 Park